FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis

Go back to FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Regeneron (NASDAQ: REGN) Delayed: 805.67 -1.81 (0.22%)
Previous Close $807.48    52 Week High $592.36 
Open $806.74    52 Week Low $325.35 
Day High $813.86    P/E 211.46 
Day Low $800.24    EPS $3.81 
Volume 581,048       

SANOFI (NASDAQ: SNY) Delayed: 40.97 -0.43 (1.04%)
Previous Close $41.40    52 Week High $44.76 
Open $41.20    52 Week Low $36.81 
Day High $41.54    P/E N/A 
Day Low $40.84    EPS $0.00 
Volume 3,110,594